异基因造血干细胞移植治疗原发性血小板增多症转化的急性髓系白血病三例报告及文献复习
回顾性分析3例原发性血小板增多症(ET)转化急性髓系白血病(AML)患者的临床特征、实验室检查及诊治经过并复习文献。3例均顺利完成异基因造血干细胞移植(allo-HSCT),移植后均达完全缓解,染色体核型正常,JAK2基因突变转阴,WT1基因表达均<200拷贝/10 000 ABL拷贝,未发生严重并发症。作者认为ET转化的AML病情凶险,allo-HSCT是目前唯一可能治愈此疾病的方法。
要点
- 3例ET转化AML患者移植前情况:例1未缓解,例2缓解后短期复发,例3出现中枢神经系统侵犯。
- 3例均顺利完成allo-HSCT,移植后均达完全缓解,染色体核型正常,JAK2基因突变均转阴。
- 作者认为ET转化的AML病情凶险,allo-HSCT是目前唯一可能治愈此疾病的方法。
核心结论
- ET转化的AML病情凶险,allo-HSCT是目前唯一可能治愈此疾病的方法。
研究设计与样本
- 回顾性分析3例ET转AML患者的临床特征、实验室检查结果及诊治经过,并复习相关文献。
主要发现
- 例1,男,44岁,初诊ET时PLT 500×10(9)/L,3年后疾病转变为骨髓增生异常综合征时WT1基因由初诊时77拷贝/10 000 ABL拷贝升至13 171拷贝/10 000 ABL拷贝,染色体核型发生异常改变,在地西他滨治疗过程中快速进展为AML。
- 例2,男,58岁,诊断ET时PLT 2 100×10(9)/L,9年后疾病进展为AML,WT1基因由初诊时130拷贝/10 000 ABL拷贝升至3 222拷贝/10 000 ABL拷贝,在化疗期间短期内复发。
- 例3,男,60岁,初诊ET时PLT 900×10(9)/L,5年后疾病转化为AML,WT1基因由初诊时56拷贝/10 000 ABL拷贝升至3 696拷贝/10 000 ABL拷贝,化疗期间出现中枢神经系统侵犯。
- 例1移植前未缓解,例2缓解后短期内复发,例3出现髓外侵犯;3例患者均顺利完成allo-HSCT,移植后骨髓缓解,染色体核型正常,例3中枢神经系统病灶消失,JAK2基因突变均转阴,WT1基因表达均<200拷贝/10 000 ABL拷贝,未发生严重并发症。
临床怎么用
- 作者认为ET转化的AML病情凶险,allo-HSCT是目前唯一可能治愈此疾病的方法。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To investigate the characteristics of the essential thrombocythemia (ET) cases transformed to the acute myeloid leukemia (AML) and the role of allogeneic hematopoietic stem cell transplantation (allo-HSCT) in the treatment of this disease. Methods: The clinical and laboratory characteristics of 3 ET cases before and after transformation and after allo-HSCT were retrospectively analyzed, meanwhile the related literatures were reviewed and discussed. Results: Case 1 was a male patient of 44 years old, whose PLT was 500×10(9)/L when firstly diagnosed ET. After 3 years the disease progressed into myelodysplastic syndrome (MDS) while WT1 expression increased from 77 (first visit) to 13 171 copies/10 000 ABL copies, at the same time chromosome changed dramatically. During the period of decitabine treatment the disease processed into AML. Case 2 was a male of 58 years old whose PLT was 2 100×10(9)/L when firstly diagnosed ET. The disease progressed to AML after 9 years, whose WT1 expression increased from 130 (first visit) to 3 222 copies/10 000 ABL copies, and he relapsed shortly after intensive chemotherapy. Case 3 was a male of 60 years old whose PLT was 900×10(9)/L when firstly diagnosed ET. The disease progressed to AML after 5 years, whose WT1 increased from 56 (first visit) to3 696 copies/10 000 ABL copies. Moreover leukemia spread to central nervous system (CNS) during chemotherapy. Before allo-HSCT, cases 1 did not achieve remission; case 2 relapsed after a short time of remission and case 3 transferred to CNS leukemia. All of the 3 cases underwent allo-HSCT successfully, and they all achieved completely remission, whose chromosome and gene mutation recovered negative. At the same time, CNS leukemia of case 3 disappeared. The median WT1 decreased to 50 copies/10 000 ABL copies. There was no severe complication during the median time of 5 months after allo-HSCT. Conclusions: The patients transformed to AML had poor prognosis, allo-HSCT was the only method that can cure the disease now. 目的: 探讨原发性血小板增多症(ET)转化急性髓系白血病(AML)的病情变化特点及异基因造血干细胞移植(allo-HSCT)的治疗价值。 方法: 回顾性分析3例ET转AML患者的临床特征、实验室检查结果及诊治经过,复习相关文献。 结果: 例1,男,44岁,初诊ET时PLT 500×10(9)/L,3年后疾病转变为骨髓增生异常综合征时WT1基因由初诊时77拷贝/10 000 ABL拷贝升至13 171拷贝/10 000 ABL拷贝,染色体核型发生异常改变,在地西他滨治疗过程中快速进展为AML。例2,男,58岁,诊断ET时PLT 2 100×10(9)/L,9年后疾病进展为AML,WT1基因由初诊时130拷贝/10 000 ABL拷贝升至3 222拷贝/10 000 ABL拷贝,在化疗期间短期内复发。例3,男,60岁,初诊ET时PLT 900×10(9)/L,5年后疾病转化为AML,WT1基因由初诊时56拷贝/10 000 ABL拷贝升至3 696拷贝/10 000 ABL拷贝,化疗期间出现中枢神经系统侵犯。例1移植前未缓解,例2缓解后短期内复发,例3出现髓外侵犯。3例患者均顺利完成allo-HSCT,移植后骨髓缓解,染色体核型正常,例3中枢神经系统病灶消失,JAK2基因突变均转阴,WT1基因表达均<200拷贝/10 000 ABL拷贝,未发生严重并发症。 结论: ET转化的AML病情凶险,allo-HSCT是目前唯一可能治愈此疾病的方法。.
引用
- Zong XP, Tang L, Cen JN, et al. [Allogeneic hematopoietic stem cell transplantation for the treatment of acute myeloid leukemia with primary thrombocytosis: three cases report and literatures review]. Zhonghua Xue Ye Xue Za Zhi. 2017. PMID: 29166742. doi:10.3760/cma.j.issn.0253-2727.2017.10.011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。